We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Gene Found to Be Associated with SIDS

By HospiMedica staff writers
Posted on 05 Feb 2003
Researchers have discovered a positive association between sudden infant death syndrome (SIDS) and the 5-HTT gene, which they say may lead to the ability to identify infants at risk for SIDS. More...
Their discovery was reported in the January 17, 2003 online edition of the American Journal of Medical Genetics.

The study was prompted by previous observations of decreased serotonergic receptor binding in SIDS cases. The 5-HTT gene regulates membrane uptake of serotonin and was therefore considered a likely candidate for SIDS studies. The investigators, from Rush-Presbyterian-St. Luke's Medical Center (Chicago, IL, USA), collected DNA samples from 87 US SIDS cases and from two sets of control subjects. The first set was screened for family history of SIDS and then matched to the SIDS cases for ethnicity and gender. The second set of controls included 33 random DNA samples used to determine population genotype frequencies. For each DNA sample, the 5-HTTLPR polymorphism was genotyped.
The results showed a significant positive association between SIDS and the L/L genotype and between SIDS and the 5-HTT L allele, and a negative association between SIDS and the S/S genetoype. SIDS cases were more likely than controls to have the long allele in the Japanese, Caucasian, and African-American study samples.

"If a larger data set reflects observations similar to those in this report,” the authors conclude, "the serotonergic system will represent a key area for further investigation into the casual basis for SIDS, with the goal of identifying genetic risk factors that will aid in recognizing at-risk individuals who require specialized intervention strategies and in counseling families as to the risk of recurrence.”




Related Links:
Rush-Presbyterian-St. Luke's Medical Center

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.